Financial Data and Key Metrics Changes - Total revenue for 2025 grew by 38% to $1.4 billion, with royalty revenue increasing by 52% to $868 million, reflecting strong performance from ENHANZE-enabled products [9][17] - Net income for the full year was $316.9 million, down from $444.1 million in 2024, impacted by a $285 million acquired IP R&D expense [19] - Adjusted EBITDA was $657.6 million, compared to $632.2 million in 2024, indicating operational strength despite the IP charge [19] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10] - PHESGO's royalty revenue increased by 51% to $105.6 million, with total sales growing 48% year-over-year to approximately $3 billion [11] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12] Market Data and Key Metrics Changes - ENHANZE now has 10 global blockbuster opportunities, with significant approvals in the U.S., Japan, and China for various products [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13] Company Strategy and Development Direction - The company aims to expand its ENHANZE pipeline, projecting 6 new programs to enter phase one in 2026, bringing the total development portfolio to 15 products [24] - The strategy includes pursuing additional licensing agreements and evaluating new drug delivery technologies to enhance long-term revenue streams [27][28] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, emphasizing the durability of royalty revenue and the potential for exceptional value creation [23] - The company anticipates continued strong growth driven by existing products and new collaborations, with a focus on expanding into new therapeutic areas [25][36] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities and extending IP into the mid-2040s [6][27] - The balance sheet was strengthened with the issuance of convertible notes and an upsized revolving credit facility, reducing near-term refinancing risk [21] Q&A Session Summary Question: Regarding the DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42] Question: On the ADC strategy and regulatory paths - The regulatory pathway for converting ADCs from IV to subcutaneous is expected to follow traditional PK non-inferiority studies, with additional trials for unapproved products [50] Question: Update on Hypercon products and clinical testing - Two Hypercon products are on track for phase 1 clinical testing in 2026, with completion of clinical scale-up batches and IND filings underway [66] Question: Potential incremental royalty opportunities from Merus's petosemtamab - Management highlighted the potential for expanded indications and the importance of subcutaneous formulations in enhancing patient treatment experiences [58]

Financial Data and Key Metrics Changes - Total revenue grew 38% to $1.4 billion, with royalty revenue increasing 52% to $868 million for the full year 2025 [9][17][19] - Net income for the full year was $316.9 million, compared to $444.1 million in 2024, while adjusted EBITDA was $657.6 million, up from $632.2 million in 2024 [19][20] - GAAP diluted EPS was $2.50, down from $3.43 in 2024, while non-GAAP diluted EPS was $4.15, compared to $4.23 in 2024 [19][20] Business Line Data and Key Metrics Changes - DARZALEX Subcutaneous generated $483 million in royalty revenue, a 29% year-over-year growth, with total sales reaching $14.4 billion [10][19] - Phesgo's royalty revenue increased 51% year-over-year to $105.6 million, with total sales growing 48% to approximately $3 billion [11][19] - VYVGART and VYVGART Hytrulo saw a 444% year-over-year growth in royalty revenues to $157.2 million, with total sales reaching $4.15 billion [12][19] Market Data and Key Metrics Changes - ENHANZE-enabled products now include 10 global blockbuster opportunities, with significant approvals in multiple markets including the U.S., Japan, and China [8][16] - The subcutaneous formulations of Ocrevus, Opdivo, RYBREVANT, and Tecentriq represent a combined market opportunity of approximately $30 billion by 2028 [13][16] Company Strategy and Development Direction - The company aims to expand its ENHANZE portfolio with six new programs entering phase I in 2026, bringing the total development portfolio to 15 products [24][35] - Hypercon technology is expected to meet the demand for lower volume, auto-injector-ready therapies, with projections of approximately $1 billion in royalty revenue within five years of the first launches [26][27] - The company plans to pursue strategic acquisitions to enhance its drug delivery portfolio while maintaining financial discipline [27][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the company, highlighting multiple revenue drivers and the durability of royalty revenue [23][39] - The company anticipates continued strong growth from existing products and new launches, with a focus on expanding into new therapeutic areas [24][35] Other Important Information - The company completed acquisitions of Elektrofi and Surf Bio, enhancing its drug delivery capabilities with long-duration IP [6][27] - The company expects to maintain a strong balance sheet and reduce net debt to below 1x by the end of 2026 [21][22] Q&A Session Summary Question: Regarding the mechanics of DARZALEX collaboration with J&J - Management expects to enter discussions with J&J to extend the agreement closer to its expiration in 2032, emphasizing the importance of the partnership [42][43] Question: On the ADC strategy and regulatory paths - Management indicated that the regulatory pathway for converting IV to subcutaneous delivery would likely follow traditional PK non-inferiority studies [49][50] Question: Update on Hypercon products and clinical testing - Management confirmed that two Hypercon products are on track for phase I clinical testing in 2026, with completion of clinical scale-up batches underway [63][64] Question: Expectations for new partnerships in auto-injectors - Management anticipates progress with high-volume auto-injectors and expects to see interest from both current and new partners [75][76]

Core Insights - Bristol Myers Squibb's (BMY) revenue performance in 2025 shows a transition with growth from new products offsetting declines in legacy drugs [1][9] - Total revenues were flat year over year, with a 17% increase in sales from the growth portfolio and a 15% decline in legacy products due to generic competition [1][9] Legacy and Growth Portfolio - The legacy portfolio, including drugs like Eliquis, Revlimid, Pomalyst, Sprycel, and Abraxane, is under pressure due to loss of exclusivity for four drugs [2] - The growth portfolio, featuring drugs such as Opdivo, Opdivo Qvantig, Orencia, and others, is crucial for maintaining revenue stability [2] Immuno-Oncology and Key Drug Performance - The immuno-oncology (IO) portfolio, particularly Opdivo, continues to show strong sales momentum due to label expansions and market share growth [3] - Opdivo Qvantig's approval has contributed to growth, with robust initial uptake across approved tumor types in the U.S. [4] - Reblozyl has achieved an annualized sales run rate above $2 billion, while Breyanzi has surpassed $1 billion in annualized sales [5] Future Outlook and Competition - Management anticipates a further decline of 12-16% in legacy sales for 2026, guiding revenues to $46.0-$47.5 billion [7] - BMY faces increasing competition in oncology from companies like Merck, particularly with the success of Keytruda [8][10] Market Performance and Valuation - BMY's shares have gained 12.7% over the past year, compared to the industry's growth of 19.6% [13] - The company is trading at a price/earnings ratio of 9.80x forward earnings, which is lower than the large-cap pharma industry's average of 18.82x [14] Earnings Estimates - The Zacks Consensus Estimate for 2026 EPS has increased to $6.15 from $6.04, while the estimate for 2027 has risen to $5.94 [17]

Industry Overview - The fourth-quarter 2025 reporting season for the Medical sector is nearing its final stretch, with only a few pharma and biotech companies left to report [1] - As of February 11, 73.3% of companies in the Medical sector, representing 91% of the sector's market capitalization, reported quarterly earnings, with 86.4% exceeding both earnings and sales estimates [2][10] - Overall, fourth-quarter earnings in the medical sector are expected to decrease by 0.6%, while sales are projected to rise by 10.4% compared to the previous year [4] Company Performance Johnson & Johnson - Reported strong fourth-quarter results, beating estimates for both earnings and sales [3] Novartis - Beat earnings estimates but faced revenue pressure due to generic competition for key drugs like Entresto and Promacta [3] Bristol Myers Squibb - Beat both earnings and sales estimates and issued encouraging guidance [3] Gilead Sciences - Earnings exceeded both top and bottom lines, supported by higher sales of HIV and Liver Diseases drugs [3] Bausch Health - Mixed performance with two earnings beats and two misses in the last four quarters, delivering a four-quarter average negative surprise of 6.26% [5] - Scheduled to report on February 18, with an Earnings ESP of -8.84% and a Zacks Rank 3 [7] Amicus Therapeutics - Disappointing earnings track record with three misses and one beat in the last four quarters, averaging a negative surprise of 20.21% [8] - Set to be acquired by BioMarin, with its lead drug Galafold showing solid uptake [9] BioMarin Pharmaceutical - Impressive track record, beating earnings estimates in each of the last four quarters with an average surprise of 66.51% [11] - Scheduled to report with an Earnings ESP of -3.23% and a Zacks Rank 3, driven by strong demand for its dwarfism drug Voxzogo [12] Insmed - Poor earnings track record with four consecutive misses, averaging a negative surprise of 20.64% [13] - Scheduled to report on February 19, with an Earnings ESP of +7.01% and a Zacks Rank 3 [14] - Lead drug Arikayce gaining traction, with a new drug approval marking a significant milestone [15] Madrigal Pharmaceuticals - Missed earnings expectations in three of the last four quarters, with an average negative surprise of 17.17% [16] - Scheduled to report on February 19, with an Earnings ESP of -852.37% and a Zacks Rank 4 [16][17]

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is recognized as a strong investment opportunity by hedge funds, with multiple analysts raising price targets and maintaining positive ratings on the stock [1][2][3] Group 1: Analyst Ratings and Price Targets - Bernstein reiterated a Hold rating on Bristol-Myers Squibb with a price target of $58.00 as of February 10 [1] - Morgan Stanley raised its price target from $37 to $40 while maintaining an Underweight rating, citing that the 2026 revenue and EPS guidance exceeded consensus due to a higher-than-expected Eliquis guide [1] - BofA increased its price target from $64 to $68 and maintained a Buy rating, noting that the company delivered fiscal Q4 and FY26 guidance beats, emphasizing that Bristol-Myers is a "pipeline story" [2] - Guggenheim raised its price target from $62 to $72, maintaining a Buy rating and increasing the odds of success for key drugs iber/mezi and milvexian to 90% [3] Group 2: Company Overview - Bristol-Myers Squibb is a biopharmaceutical company focused on discovering, developing, and delivering advanced medicines for serious diseases across various therapeutic classes, including hematology, oncology, cardiovascular, immunology, and neuroscience [4]

Core Insights - Bristol Myers Squibb (BMS) reported a total revenue of $48.194 billion for 2025, nearly flat compared to $48.300 billion in 2024, but achieved a significant turnaround in GAAP net profit from a loss of $8.948 billion in 2024 to a profit of $7.054 billion in 2025, with Non-GAAP net profit soaring over 430% from $2.340 billion to $12.545 billion [1][2] Group 1: Financial Performance - The growth product portfolio generated $26.409 billion in revenue, accounting for over 54.8% of total revenue, marking a 17% increase year-over-year [1][3] - Traditional products, including Revlimid and Pomalyst, saw a significant revenue decline of 15%, contributing only $21.785 billion [1][3] Group 2: Product Performance - Revlimid's sales plummeted nearly 49% to $2.951 billion, primarily due to generic competition, with Pomalyst also facing a 54% decline in international sales [3][4] - Eliquis generated $14.443 billion in sales, reflecting an 8% increase, with expectations of 10% to 15% growth in 2026 [4][8] Group 3: Strategic Initiatives - BMS completed five strategic transactions in 2025, including a notable $1.5 billion collaboration with BioNTech to develop a next-generation bispecific antibody [7][8] - The company is shifting its focus from a few blockbuster drugs to a diversified product matrix, with more products exceeding $1 billion in sales [6][8] Group 4: Future Outlook - BMS anticipates a revenue guidance of $46 billion to $47.5 billion for 2026, indicating a cautious outlook amid ongoing challenges from patent expirations [11] - The company is actively pursuing opportunities in cell therapy for autoimmune diseases and expects significant data readouts in 2026 for several key products [9][10]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for energy to support its growth [1][2][3] AI and Energy Demand - AI technologies, particularly large language models like ChatGPT, are extremely energy-intensive, with data centers consuming as much energy as small cities [2] - The increasing demand for AI is straining global power grids, leading to rising electricity prices and utilities struggling to expand capacity [2] Investment Opportunity - A specific company, largely overlooked by AI investors, is positioned to benefit from the anticipated surge in energy demand due to AI [3][6] - This company owns critical energy infrastructure assets and is involved in the U.S. LNG exportation sector, which is expected to grow under the current administration's energy policies [7][8] Financial Position - The company is noted for being debt-free and holding a significant cash reserve, amounting to nearly one-third of its market capitalization [8] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities without high premiums [9] Market Perception - Wall Street is beginning to take notice of this company due to its unique position in the energy sector, which is essential for supporting AI advancements [8][10] - The company is trading at a low valuation of less than 7 times earnings, making it an attractive investment option compared to other firms in the energy and utility sectors [10] Future Outlook - The ongoing AI revolution is expected to disrupt traditional industries, with companies that adapt to AI technologies likely to thrive [11][12] - The influx of talent into the AI sector is anticipated to drive continuous innovation and advancements, reinforcing the importance of investing in AI [12][13] Strategic Context - The company is strategically aligned with trends such as the AI infrastructure supercycle, the onshoring boom due to tariffs, and a surge in U.S. LNG exports [14]

Group 1 - Steven Cress is the Head of Quantitative Strategies at Seeking Alpha, managing quant ratings and factor grades on stocks and ETFs [1][2] - Cress leads Alpha Picks, selecting two attractive stocks to buy each month and determining when to sell them [1][2] - The Seeking Alpha Quant Rating system, created by Cress, interprets data for investors and offers insights on investment directions [2] Group 2 - Cress has over 30 years of experience in equity research, quantitative strategies, and portfolio management, enhancing his expertise in investment topics [2] - Prior to Seeking Alpha, Cress founded CressCap Investment Research and Cress Capital Management, and worked at Morgan Stanley and Northern Trust [2]

Financial Performance - Total revenues for 2025 were $48,194 million, a slight decrease from $48,300 million in 2024 and an increase from $45,006 million in 2023[15]. - The United States accounted for 69% of total revenues in 2025, down from 71% in 2024, while international revenues increased to 29% from 27%[15]. Product Development and Innovation - The company focuses on innovative medicines in oncology, hematology, immunology, cardiovascular, and neuroscience, aiming for long-term value creation[14]. - Key marketed products include Opdivo, Yervoy, and Breyanzi, with ongoing potential for expansion in various cancer treatments[19]. - The growth portfolio includes innovative therapies such as CAR-T cell therapies and biologics, which are expected to contribute to future revenue growth[18]. - The R&D pipeline focuses on oncology, hematology, immunology, cardiovascular diseases, and neuroscience, with an emphasis on novel modalities such as cell therapies and biologics[58]. - The company has over 45 unique assets in its development pipeline, emphasizing a balance of early-stage and late-stage programs[66]. - The company has a diverse pipeline of investigational compounds, including BMS-986495 for Alzheimer's Disease and COBENFY for schizophrenia, with multiple indications in various phases of development[82]. Regulatory and Market Exclusivity - Regulatory exclusivity for biologics lasts 12 years, while chemical products receive 5 years, impacting the competitive landscape for the company's offerings[32][31]. - The estimated minimum market exclusivity date for Abecma in the U.S. is 2036, in the EU is 2035, and in Japan is 2037[46]. - Eliquis has a patent expiration in the U.S. set for 2028, with generics allowed to launch under settlement agreements, while in the EU, the relevant patents expire in November 2026[50]. - The EU provides an "8+2+1" regulatory exclusivity regime, allowing generics to file for marketing authorization after 8 years, but they cannot commercialize until 10 or 11 years have passed[38]. - In Japan, new chemical entities receive 8 years of regulatory exclusivity, which can be extended if pediatric studies are completed[40]. Research and Development (R&D) Investments - R&D expenses were $10.0 billion in 2025, $11.2 billion in 2024, and $9.3 billion in 2023, with acquired IPRD expenses of $3.7 billion in 2025, $13.4 billion in 2024, and $913 million in 2023[63]. - The company opened R&D facilities in Cambridge, Massachusetts in 2023 and Hyderabad, India in 2024, and plans to open a new facility in San Diego, California in 2026[65]. - The company considers registrational studies as significant R&D programs, which may include investigational compounds in Phases II and III development[61]. - The company supplements its internal R&D with acquisitions, alliances, and collaborative agreements to enhance its pipeline[66]. - The company emphasizes leadership, innovation, productivity, and quality as key strategies for success in its R&D activities[66]. Manufacturing and Supply Chain - The company has significant manufacturing operations in the U.S., Puerto Rico, the Netherlands, Ireland, and Switzerland, supporting its global distribution strategy[14]. - The company completed the construction of new state-of-the-art cell therapy manufacturing facilities in Devens, Massachusetts in 2023 and in Leiden, Netherlands in 2025[65]. - The company continues to invest in its manufacturing capabilities, including a radiopharmaceutical manufacturing facility opened in Indianapolis, Indiana in 2025[65]. - The company is expanding its use of third-party manufacturers for drug product and finished goods manufacturing to maintain a stable supply of products[123]. - The company has a flexible manufacturing network to improve efficiency and minimize unnecessary product transfers, which is crucial given the complexity of pharmaceutical manufacturing processes[121]. Market Competition and Pricing Strategies - The company faces competition from both global research-based drug companies and generic manufacturers, necessitating a focus on innovation and market differentiation[14]. - The company faces intense competition in the oncology market, particularly for its IO products like Opdivo, which are subject to competition from both existing and new therapies[95]. - Pricing strategies are influenced by the clinical value of innovations and the need to sustain investment in R&D, with a focus on enhancing patient access through tiered pricing and support programs[99]. Regulatory Environment and Compliance - The company is subject to extensive global regulations affecting product testing, approval, and marketing, which can delay product introductions[102]. - The FDA's regulatory review process is resource-intensive, impacting the time and cost to bring new products to market[103]. - The company is monitoring state laws seeking additional rebates and limiting drug spending due to budget pressures[100]. - Multiple states are pursuing legislation to change drug pricing and reimbursement, which could significantly impact access, coverage, and reimbursement of products, potentially affecting revenues and operations[118]. Employee and Operational Management - As of December 31, 2025, the company employed approximately 32,500 employees across 43 countries, with 54% located in the U.S. and 46% outside the U.S.[132]. - The company is investing in next-generation platforms for employee development, including tools for internal mobility and just-in-time learning resources[134]. - The company maintains a commitment to quality across all operations, ensuring product safety and effectiveness through rigorous testing and quality control measures[125]. Financial Risks and Currency Exposure - Company is exposed to significant foreign exchange risk, primarily with the euro and Japanese yen, affecting revenues, earnings, and cash flow[377]. - A 10% appreciation in the currencies being hedged would decrease the fair value of foreign exchange contracts by $428 million and $455 million as of December 31, 2025 and 2024, respectively[378]. - Cross-currency swap contracts are used to manage risks from long-term debt in euros, with a 10% appreciation in the underlying currencies decreasing the fair value of these contracts by $8 million in 2025 and increasing it by $49 million in 2024[379]. - A 1% increase in long-term interest rates would decrease the fair value of long-term debt by $3.5 billion and $3.6 billion as of December 31, 2025 and 2024, respectively[382]. - Company employs fixed-to-floating interest rate swap contracts to balance fixed and floating rate debt, with no material adverse impact expected from a 1% increase in interest rates[381]. - Company monitors investments to minimize credit risk, only investing in high credit quality institutions[383]. - Derivative instruments expose the company to credit risk if counterparties fail to perform, with a policy in place to diversify derivatives to mitigate this risk[384].

Summary of BMS Q4 2025 and Full Year Performance Company Overview - The document discusses Bristol-Myers Squibb (BMS), a major player in the pharmaceutical industry, focusing on its Q4 2025 and full-year performance metrics. Key Financial Metrics - **Q4 2025 Revenue**: BMS achieved revenue of $12.5 billion, with growth portfolio sales at $7.4 billion (+15%) and legacy portfolio sales at $5.1 billion (-16%) [1] - **Full Year 2025 Revenue**: Total revenue for 2025 was $48.2 billion (-1%), with growth portfolio sales at $26.4 billion (+17%) and legacy portfolio sales at $21.8 billion (-16%) [1] 2026 Revenue Guidance - BMS updated its 2026 revenue guidance to a range of $46 billion to $47.5 billion (-5% to -1%) [2] - Non-GAAP EPS guidance was set between $6.05 and $6.35 per share [2] Product Performance Highlights Oncology - **Opdivo (Nivolumab)**: Sales reached $2.69 billion (+7%), driven by volume growth and new approvals [2] - **Yervoy (Ipilimumab)**: Sales were $810 million (+18%) [2] - **Opdualag**: Sales of $350 million (+37%), with a 30%+ market share in 1L melanoma in the US [2] Hematology - **Revlimid (Lenalidomide)**: Sales dropped to $600 million (-55%) due to generic competition [2] - **Pomalyst**: Sales were $690 million (-16%) [2] - **Reblozyl**: Sales increased to $670 million (+21%), driven by demand for 1L treatment of MDS-related anemia [2] - **Breyanzi**: Sales reached $390 million (+47%), primarily driven by demand in LBCL [2] Cardiovascular - **Eliquis (Apixaban)**: Sales were $3.45 billion (+6%), with US and ex-US sales growing by 4% and 9% respectively; 2026 global revenue growth is expected at 10% to 15% [3] - **Camzyos**: Sales of $350 million (+57%) [3] - **Milvexian**: Phase 3 clinical study terminated due to interim analysis not meeting efficacy [3] Immunology - **Orencia (Abatacept)**: Sales remained stable at $1.01 billion [3] - **Sotyktu**: Sales of $86 million (+3%), with a PDUFA date for PsA indication set for March 6, 2026 [3] Neurology - **Cobenfy**: Sales of $51 million [3] - **Zeposia**: Sales of $160 million (-1%), primarily contributed by MS indication [3] Additional Insights - The document highlights the impact of generic competition on legacy products and the growth potential in the growth portfolio, particularly in oncology and cardiovascular segments [2][3] - The anticipated decline in revenue for Eliquis in 2027 is noted, with a projected drop of $1.5 billion to $2 billion [3]